申请人:Illig Carl R.
公开号:US20070249593A1
公开(公告)日:2007-10-25
The invention is directed to compounds of Formula I:
wherein Z, X, J, R
2
and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
本发明涉及式I化合物:其中Z、X、J、R2和W在说明书中规定,以及抑制蛋白酪氨酸激酶,尤其是c-fms激酶的溶剂化物、水合物、互变异构体和药用盐。治疗自身免疫病;和治疗具有炎症成分的疾病;治疗来自卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移;和治疗疼痛,包括由肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏、炎症性和神经性疼痛;以及骨质疏松症、佩吉特病,以及骨吸收介导病状的其它疾病,包括类风湿性关节炎、其它形式的炎症性关节炎、骨关节炎、假体失败、溶骨肉瘤、骨髓瘤和骨转移瘤,也提供了式I化合物。